DOCSLIB.ORG

Read the GPC 2020 Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Read the GPC 2020 Report Report Co-creation in Innovative Healthcare during COVID-19 11th January 2021 Contents We have found that the Executive Summary ......................................................3 factors that helped countries Acknowledgements ......................................................5 respond and cope better Partners ...........................................................................6 to the COVID-19 pandemic Message of condolence .............................................7 included strong political Background.....................................................................9 leadership, a reliance on Aims and objectives of GPC 2020 ......................... 11 GPC 2020 Theme ............................................................13 science and public health Introduction to Programme Sessions ..........................14 experts to shape the strategy, Day One ....................................................................... 14 being open and transparent Opening Ceremony ................................................... 14 with the public, having clear Keynote Speech .......................................................... 16 communications lines and Sessions ........................................................................ 18 having citizens involvement Day Two ............................................................................33 and empowerment to Keynote Speech .......................................................... 33 Keynote Speech .......................................................... 34 act within the guidelines Sessions ........................................................................ 35 they receive and trust Final Remarks ...................................................................53 between government and GPC 2020 Call to Action .......................................... 56 their citizens. Resources and Inputs ............................................... 57 Booth Visits .................................................................. 58 Dr Soumya Swaminathan, MD, Outputs, Outcomes and Impact ............................ 59 Chief Scientist, World Health GPC 2020 Information ....................................................61 Organization Programme ................................................................. 61 Delegates’ Attendance .............................................. 68 List of Speakers .......................................................... 70 IAPO Staff ..................................................................... 90 Executive Summary The 9th Global Patients Congress (GPC 2020) was meant to be a celebratory event to mark our twenty first anniversary and the coming of age of patient centred healthcare globally. However, the COVID-19 pandemic overtook all of us manufacturers, Industry representatives from the five revealing great fault lines in our health systems and Covid-19 candidate vaccines then laid out the route plan shifted all our membership’s focus as most of them on how quickly they would be ready and what needs to had to rapidly assist their patient communities and be done. governments to develop effective shielding programmes Expert patients, policy makers and practitioners coming for very vulnerable patients. from 28 countries organised in 27 thematic panels then The pandemic was a catastrophe for patient-centred delivered the remaining 64 insightful presentations. The healthcare and the social welfare and mental health sessions paved the road to discussing: wellbeing of our patients was adversely impacted as the • The health crisis provoked by COVID-19 worldwide unplanned lockdowns ensured that most healthcare and its impact on the patient community; services and access to medicines and psychosocial support were disrupted. • How to realise the World Health Organization (WHO)’s commitment to “build back better” and The GPC 2020 had to take place virtually under a new ensure the implementation of the World Health theme “Co-creation in Innovative Healthcare during Assembly Resolution 73.1 COVID-19 response; COVID-19” on 16-17 September 2020. • The next steps for strengthening health systems and GPC 2020 Virtual brought together 1300 delegates from preparedness through patient led and co-created 101 countries and nearly 400 patient groups. We were innovative solutions post COVID-19 and in future. also happy to virtually meet representatives from 98 IAPO member organizations live while others accessed Throughout GPC 2020, speakers raised key issues the recordings on www.gpc2020.vfairs.com. and delivered unique take-home messages. These included the importance of all WHO Member States and The GPC 2020 opened with a Keynote from WHO Chief pharmaceutical industry to keep cooperating and sharing Scientist Dr Soumya Swaminathan, Chief Scientist who knowledge and resources in the fight against COVID-19. brought everyone up to date on the fast progress All Speakers also agreed on the importance of patients’ being made on World Health Assembly Resolution 73.1 engagement to address the ‘infodemic’ and vaccine Covid-19 response and the impact COVID-19 was having hesitation, and their participation in health systems all on existing WHO programmes on Maternal and New over the world. Born Health, TB, Malaria and NCDs. Under the umbrella of the International Federation of Pharmaceutical 3 Day 2 of GPC 2020 marked the 2nd World Patient Safety Day (WPSD). At IAPO we know how crucial safety is for all patients seeking healthcare. However, safety in health systems is a global concern because of increasing numbers of people suffering avoidable harm or being put at risk of injury while receiving healthcare. IAPO invited Hon. Jeremy Hunt MP the Chief Architect of stakeholders to stand together in our call for safe the Global Ministerial Patient Safety Summits and former patient-centred healthcare as an essential component UK Secretary of State for Health and Social Care to open for the achievement of universal health coverage. with a keynote. The theme for WPSD 2020 was ‘Health worker safety: Recognising the urgency of the issue, on 17th September A priority for patient safety’. This theme was selected 2020, health stakeholders from all over the world stood given the current challenges health workers were facing together, united in observing the WPSD. The COVID-19 with regards to their physical and mental health and pandemic has unveiled the serious difficulties health safety amid the COVID-19 pandemic. The slogan ‘Safe workers are facing worldwide while responding to health workers, Safe patients’ reflects the interlinkages this unprecedented global public health challenge. between health workers safety and patient safety. World Patient Safety Day 2020 was an opportunity to Services cannot be delivered safely if health worker safety emphasize the importance of health worker safety as itself is not prioritized and addressed. a priority for patient safety by committing and taking The WPSD 2020 therefore called on WHO Member urgent and sustainable action to recognize health States and partners to ‘Speak up for Health Workers worker safety as a prerequisite for patient safe. This Safety!’ urging them to prioritize and address the issue in was a unique opportunity for patients, patients’ groups, a holistic manner. carers, civil society organizations and other relevant Acknowledgements We would like to thank the GPC 2020 Committee: We first want to thank all the health professionals and frontline health workers who have been putting themselves at great risk to take care of patients during the current Karen Alparce- Dr Ratna Devi Dr Neda Milevska COVID-19 pandemic. Villaneuva (Chair) Many have made the ultimate sacrifice and lost their lives in serving us. We pass our condolences to their families. In this year of the Year of the Nurse and the Midwife 2020, we acknowledge the great support given to us by the International Council of Nurses during this pandemic. We also want to thank our members, industry partners, collaborating partners and supporters who made the Kawaldip Sehmi Sabine Nick Bisi Bright 9th Global Patients Congress a great success despite the difficult circumstances that they are all facing. They stepped forward to help in planning the event by joining our GPC Organising Committee and later as moderators and speakers during the congress. Our special thanks go to the World Health Organization (WHO) and its Secretariat and specifically the WHO Patient Safety and Quality Improvement Unit in the Dani Mothci Rachel Githinji Service Delivery and Safety Department for helping us mark a great 2nd World Patient Safety Day on 17th GPC 2020 Rapporteurs: September 2020. We particularly want to thank Dr. Soumya Swaminathan, Dr. Neelam Dhingra, Dr. Ivana Knezevic and Joseph Kutzin for enriching our programme and sharing with our members great insight into the COVID-19 pandemic and the WHO Flagship Decade of Patients Safety 2020-2030. Monique Antonia Gama Bittencourt Da Costa Franca 5 Partners Lastly, we thank our Industry Partners without whose partnership and resources we could not have delivered this quality virtual congress. Platinum Sponsors Gold Sponsors Silver Sponsors (formerly Upjohn) 6 Message of condolence At the time of the Congress, many countries were going through the first wave of COVID-19 infections and bereavements. IAPO and its family of patient organizations shared this pain, and send out our deepest condolences to the bereaved families and friends of those who have lost their lives to COVID-19. IAPO and its
Load more

Recommended publications
  • Download PDF (2.6
    A Proposal to End the COVID-19 Pandemic Prepared by Ruchir Agarwal and Gita Gopinath* Authorized for distribution by Gita Gopinath DISCLAIMER: Staff Discussion Notes (SDNs) showcase policy-related analysis and research being developed by IMF staff members and are published to elicit comments and to encourage debate. The views expressed in Staff Discussion Notes are those of the author(s) and do not necessarily represent the views of the IMF, its Executive Board, or IMF management. Urgent steps are needed to arrest the rising human toll and economic strain from the COVID-19 pandemic that are exacerbating already-diverging recoveries. Pandemic policy is also economic policy as there is no durable end to the economic crisis without an end to the health crisis. Building on existing initiatives, this paper proposes pragmatic actions at the national and multilateral level to expeditiously defeat the pandemic. The proposal targets: (1) vaccinating at least 40 percent of the population in all countries by the end of 2021 and at least 60 percent by the first half of 2022, (2) tracking and insuring against downside risks, and (3) ensuring widespread testing and tracing, maintaining adequate stocks of therapeutics, and enforcing public health measures in places where vaccine coverage is low. The benefits of such measures at about $9 trillion far outweigh the costs which are estimated to be around $50 billion—of which $35 billion should be paid by grants from donors and the residual by national governments potentially with the support of concessional financing from bilateral and multilateral agencies. The grant funding gap identified by the Access to COVID-19 Tools (ACT) Accelerator amounts to about $22 billion, which the G20 recognizes as important to address.
    [Show full text]
  • Page 1 May 2021 SD N /2021/4
    May 2021 I M F S T A F F D I S C U S S I O N N O T E A Proposal to End the COVID-19 Pandemic SDN/2021/4 Ruchir Agarwal, Gita Gopinath DISCLAIMER: Staff Discussion Notes (SDNs) showcase policy-related analysis and research being developed by IMF staff members and are published to elicit comments and to encourage debate. The views expressed in Staff Discussion Notes are those of the author(s) and do not necessarily represent the views of the IMF, its Executive Board, or IMF management. A Proposal to End the COVID-19 Pandemic Prepared by Ruchir Agarwal and Gita Gopinath* Authorized for distribution by Gita Gopinath DISCLAIMER: Staff Discussion Notes (SDNs) showcase policy-related analysis and research being developed by IMF staff members and are published to elicit comments and to encourage debate. The views expressed in Staff Discussion Notes are those of the author(s) and do not necessarily represent the views of the IMF, its Executive Board, or IMF management. Urgent steps are needed to arrest the rising human toll and economic strain from the COVID-19 pandemic that are exacerbating already-diverging recoveries. Pandemic policy is also economic policy as there is no durable end to the economic crisis without an end to the health crisis. Building on existing initiatives, this paper proposes pragmatic actions at the national and multilateral level to expeditiously defeat the pandemic. The proposal targets: (1) vaccinating at least 40 percent of the population in all countries by the end of 2021 and at least 60 percent by the first half of 2022, (2) tracking and insuring against downside risks, and (3) ensuring widespread testing and tracing, maintaining adequate stocks of therapeutics, and enforcing public health measures in places where vaccine coverage is low.
    [Show full text]
  • Tuberculosis Diagnostic Research: Beyond the Basics December 13 - 15, 2010, Tuberculosis Research Centre, Chennai, India
    Tuberculosis Diagnostic Research: Beyond the Basics December 13 - 15, 2010, Tuberculosis Research Centre, Chennai, India COURSE SCHEDULE Monday, Dec 13, 2010 Time Lecture Faculty 8.30 AM Welcome and Introductions A Thomas, MS Jawahar, all 9.00 AM The global value chain (blueprint) for TB diagnostics and current M Pai pipeline of diagnostics 9.45 AM New WHO policy on Xpert MTB/RIF CN Paramasivan New WHO policy on serological assays K Steingart 10.30 AM Coffee 10.45 AM Overview of diagnostic research and types of diagnostic study M Pai designs 11.15 AM Landscape of TB diagnostic research M Pai 12.30 PM Lunch 1.30 PM The diagnostic test accuracy design M Pai 2.30 PM Bias in diagnostic research and sources of variation K Steingart 3.30 PM Coffee 4.00 - 5.30 PM Optimism bias in TB diagnostic research & critical appraisal M Pai Tuesday, Dec 14, 2010 Time Lecture Faculty 8.30 AM Setting reference standards in TB diagnostic studies: • Microscopy evaluations CN Paramasivan • Rapid culture methods CN Paramasivan • Molecular assays T Shinnick • Serological assays S Laal • IGRAs and LTBI tests M Pai • Extrapulmonary TB J Peter 10.30 AM Coffee 10.45 PM Lab accreditation and QA in India J Kenneth Ensuring quality in diagnostic trials: • Microscopy studies CN Paramasivan CN Paramasivan • Culture studies T Shinnick • Molecular assay studies S Laal • Immunodiagnostic studies 1 12.00 Noon Introduction to TB biomarker validation S Parida 12.30 PM Lunch 1.30 PM Beyond test accuracy - 1: impact of testing on diagnostic M Pai thinking and clinical decision
    [Show full text]
  • TB Diagnostics in India
    Content and themes This conference will convene industry leaders, innovative thinkers, A 2 researchers, funders, and policy makers, to stimulate increased - industry/biotech engagement in diagnostic innovations that can help TB conferenceday stimulate TB to diagnostics industry/biotech engagementinnovations in in India control in India and elsewhere. Sessions will focus on topics such as market size for TB diagnostics, IVD market analysis and value chain, target product profiles and market needs, frugal innovation and affordable diagnostics, intellectual property issues, regulation of diagnostics, sources of funding, prize models, business models for engaging private sector, scientific obstacles for R&D, barriers to innovation in India, academia-industry relations, and role of emerging economies and BRICS in the next wave of TB innovations. Confirmed speakers & panelists Anu Acharya, Ocimum Biosolutions, Hyderabad, India Tanjore Balganesh, AstraZeneca, Bangalore, India August 25 Steven Buchsbaum, Bill & Melinda Gates Foundation, USA Sanjeev Chaudhry, SRL, India Vir S. Chauhan, ICGEB, New Delhi, India Anand Daniel, Accel Partners, Bangalore, India Dhananjaya Dendukuri, Achira Labs, Bangalore, India TB diagnostics in India - Pradip Desai, Span Diagnostics, Surat, India 2011 26, Bindu Dey, Department of Biotechnology, New Delhi, India From importation and imitation to innovation Puneet Dewan, WHO, SEARO, New Delhi, India August 25 - 26, 2011, Bangalore, India Sami Guzder, Avesthagen, Bangalore, India Hosted by: St. John’s Research Institute,
    [Show full text]
  • The Order of Military Merit to Corporal R
    Chapter Three The Order Comes to Life: Appointments, Refinements and Change His Excellency has asked me to write to inform you that, with the approval of The Queen, Sovereign of the Order, he has appointed you a Member. Esmond Butler, Secretary General of the Order of Military Merit to Corporal R. L. Mailloux, I 3 December 1972 nlike the Order of Canada, which underwent a significant structural change five years after being established, the changes made to the Order of Military U Merit since 1972 have been largely administrative. Following the Order of Canada structure and general ethos has served the Order of Military Merit well. Other developments, such as the change in insignia worn on undress ribbons, the adoption of a motto for the Order and the creation of the Order of Military Merit paperweight, are examined in Chapter Four. With the ink on the Letters Patent and Constitution of the Order dry, The Queen and Prime Minister having signed in the appropriate places, and the Great Seal affixed thereunto, the Order had come into being, but not to life. In the beginning, the Order consisted of the Sovereign and two members: the Governor General as Chancellor and a Commander of the Order, and the Chief of the Defence Staff as Principal Commander and a similarly newly minted Commander of the Order. The first act of Governor General Roland Michener as Chancellor of the Order was to appoint his Secretary, Esmond Butler, to serve "as a member of the Advisory Committee of the Order." 127 Butler would continue to play a significant role in the early development of the Order, along with future Chief of the Defence Staff General Jacques A.
    [Show full text]
  • Recent Developments in Genomics, Bioinformatics and Drug Discovery to Combat Emerging Drug-Resistant Tuberculosis
    Tuberculosis 101 (2016) 31e40 Contents lists available at ScienceDirect Tuberculosis journal homepage: http://intl.elsevierhealth.com/journals/tube REVIEW Recent developments in genomics, bioinformatics and drug discovery to combat emerging drug-resistant tuberculosis * Soumya Swaminathan a, , Jagadish Chandrabose Sundaramurthi b, Alangudi Natarajan Palaniappan c, Sujatha Narayanan d a National Institute for Research in Tuberculosis (ICMR), Chetpet, Chennai, 600031, India b Division of Biomedical Informatics, Department of Clinical Research, National Institute for Research in Tuberculosis (ICMR), Chetpet, Chennai, 600031, India c Department of Clinical Research, National Institute for Research in Tuberculosis (ICMR), Chetpet, Chennai, 600031, India d Department of Immunology, National Institute for Research in Tuberculosis (ICMR), Chetpet, Chennai, 600031, India article info summary Article history: Emergence of drug-resistant tuberculosis (DR-TB) is a big challenge in TB control. The delay in diagnosis Received 24 February 2016 of DR-TB leads to its increased transmission, and therefore prevalence. Recent developments in genomics Received in revised form have enabled whole genome sequencing (WGS) of Mycobacterium tuberculosis (M. tuberculosis) from 3- 21 May 2016 day-old liquid culture and directly from uncultured sputa, while new bioinformatics tools facilitate to Accepted 8 August 2016 determine DR mutations rapidly from the resulting sequences. The present drug discovery and devel- opment pipeline is filled with candidate drugs which have shown efficacy against DR-TB. Furthermore, Keywords: some of the FDA-approved drugs are being evaluated for repurposing, and this approach appears Drug-resistant tuberculosis fi Whole genome sequencing promising as several drugs are reported to enhance ef cacy of the standard TB drugs, reduce drug Bioinformatics tolerance, or modulate the host immune response to control the growth of intracellular M.
    [Show full text]
  • Health Technology Assessment Stakeholder's Consultative Workshop 25Thjuly, 2016, India Habitat Centre, New Delhi, India
    Health Technology Assessment Stakeholder’s Consultative Workshop 25thJuly, 2016, India Habitat Centre, New Delhi, India Introduction On the 25th July, 2016, a workshop was jointly convened by the Department of Health research (DHR), Government of India, The Indian Council of Medical Research (ICMR), and the international Decision Support initiative (IDSI) in order to raise awareness of the initiative to institutionalise health technology assessment (HTA) in India. This initiative aims to introduce a more transparent, inclusive, fair, and evidence-based process by which decisions regarding the allocation of health resources are made in India. The official government press release for the event highlighted the interest of the Indian government to utilise the event to learn from international iDSI partners on how HTA can be best utilised to improve access to affordable health care for the people of India towards the ultimate goal of Universal Health Coverage (UHC). The workshop provided the opportunity for key stakeholders within the field to share experiences, and engage in rich discussion and debate regarding the context, need, function, structure, and future plans for this initiative. The conference was well attended with over 200 delegates, including senior members of the Indian government such as the 2 newly appointed ministers of state for health, Shri Faggan Singh Kulaste and Smt Anupriya Patel; The DG of health services, Mr Jagdish Prasad; and the secretary of DHR, Dr Soumya Swaminathan. Speakers at the event included distinguished leaders of health research and public health strategy in India, including Mr Manoj Jhalani, Joint Secretary and Mission Director (NHM), Ministry of Health and Family Welfare, Prof S.
    [Show full text]
  • Daily Report Tuesday, 14 January 2020 CONTENTS
    Daily Report Tuesday, 14 January 2020 This report shows written answers and statements provided on 14 January 2020 and the information is correct at the time of publication (06:30 P.M., 14 January 2020). For the latest information on written questions and answers, ministerial corrections, and written statements, please visit: http://www.parliament.uk/writtenanswers/ CONTENTS ANSWERS 5 Department for Digital, ATTORNEY GENERAL 5 Culture, Media and Sport 13 Katelyn Dawson 5 Gambling Act 2005 13 BUSINESS, ENERGY AND Loneliness 14 INDUSTRIAL STRATEGY 5 Passenger Ships: Standards 14 Living Wage 5 Performing Arts: Children 14 Pregnancy: Discrimination 6 Public Libraries: Closures 15 Renewable Energy 6 EDUCATION 16 Renewable Energy: Carbon Academies 16 Emissions 8 Children in Care 16 Renewable Heat Incentive Children: Day Care 17 Scheme 8 Educational Institutions: CABINET OFFICE 8 Sanitary Protection 18 Average Earnings 8 Further Education: Finance 19 Civil Servants: Recruitment 9 Schools: Land 19 Honours 9 Teachers 19 Public Bodies: Sanctions 10 Teachers: Bureaucracy 20 DEFENCE 11 ENVIRONMENT, FOOD AND Armed Forces: Oldham 11 RURAL AFFAIRS 20 Libya: Armed Conflict 11 Air Pollution: North West 20 DIGITAL, CULTURE, MEDIA AND Litter: Beaches 21 SPORT 12 Trees: New Forest 22 5G: North Herefordshire 12 EXITING THE EUROPEAN Actors: Females 12 UNION 22 Cambridge Analytica 13 Brexit 22 Brexit: Northern Ireland 22 Brexit: Scotland 23 Joint Replacements: Waiting Immigration 23 Lists 37 UK Relations with EU: Learning Disabilities Mortality Scotland 23 Review
    [Show full text]
  • Looking Forward: Avoiding a Vaccine Cold War” a Recap Featuring World Renown Scientists and Doctors Discussing the Realities of the COVID-19 Pandemic
    All the Best Podcast Episode 48: “Looking Forward: Avoiding a Vaccine Cold War” A recap featuring world renown scientists and doctors discussing the realities of the COVID-19 pandemic Dr. Murphy: The 41st president, George H. W. Bush, was known for many things, but one of which was truly the leader of a team, the assemblage of a team, the inspiration of a team. He had three aspects that he shared with me. He said in crucial things, unity, in important things, diversity and in all things generosity. George: In the first place, I believe that character is a part of being President. Barbara: And life really must have joy. Sam: This is "All the Best." The official podcast of the George and Barbara Bush Foundation. I'm your host, Sam LeBlond, one of their many grandchildren. Here, we celebrate the legacy of these two incredible Americans through friends, family, and the foundation. This is "All the Best." George: I remember something my dad taught me. He said, write your mother, serve your country, and he said, tell the truth. And I've tried to do that in public life. All through it. Barbara: You are a human being first and those human connections with children, with friends are the most important investments you will ever make. George: We stand tonight before a new world of hope and possibilities for our children. A world we could not have contemplated a few years ago. Sam: On behalf of our family and the George and Barbara Bush Foundation. This is "All the Best." ATB Podcast – Vaccine Recap Oct 2020 2 Welcome to "All the Best." I'm your host, Sam LeBlond.
    [Show full text]
  • Kaivan Munshi
    Kaivan Munshi Department of Economics Yale University Hillhouse Avenue 203-432-4479 [email protected] Education Ph.D. Economics Massachusetts Institute of Technology 1995 M.S., M.C.P. University of California, Berkeley 1989 B.Tech. Indian Institute of Technology, Bombay 1986 Honors and Awards 2019 Distinguished Alumnus Award, IIT Bombay 2016 Infosys Prize for the Social Sciences Positions Held 2020 Faculty Research Associate, National Bureau of Economic Research (NBER) 2019 Professor, Department of Economics, Yale University 2018 Associate Member, Toulouse School of Economics 2015-2019 Research Fellow, Centre for Economic Policy Research (CEPR) 2015 Research Fellow, Institute for the Study of Labor (IZA) 2015-2019 Research Fellow, Institute for Fiscal Studies (IFS) 2015-2017 Professorial Fellow, Magdalene College 2014 Research Associate, Harvard-Cambridge Joint Centre for History and Economics 2013-2019 Frank Ramsey Professor of Economics, University of Cambridge 2013 Research Fellow, Centre for Research and Analysis of Migration (CReAM) 2013 Research Associate, Population Research Institute, Pennsylvania State University 2013-2015 Visiting Senior Scholar, Department of Economics, Pennsylvania State University 2011 Associate, Theoretical Research in Development Economics (ThReD) 2010-2016 Co-editor, Journal of Development Economics 2008-2012 Permanent Member, NIH Social Sciences and Population Studies (SSPS) Study Section 2007-2012 Associate Editor, American Economic Review 2007-2008 Associate Editor, Economic Development and Cultural
    [Show full text]
  • 2020 International Cohorts Summit Executive Summary
    MEETING SUMMARY Virtual Summit Zoom May 4-5, 2020 Hosted by the Global Genomic Medicine Collaborative (G2MC) ihccglobal.org Vision for success: TO CREATE A GLOBAL NETWORK FOR TRANSLATIONAL RESEARCH THAT UTILIZES LARGE COHORTS TO ENHANCE THE UNDERSTANDING OF THE BIOLOGICAL AND GENETIC BASIS OF DISEASE AND IMPROVE CLINICAL CARE AND POPULATION HEALTH IHCC Third International Cohorts Virtual Summit Executive Summary In 2015, the National Institutes of Health (NIH) launched an effort to identify all large-scale prospective cohort studies involving at least 100,000 participants to explore the potential of bringing them together to address scientific questions none could answer alone. This effort led to the commission of the Global Genomic Medicine Collaborative (G2MC) to bring together these cohorts through the International HundredK+ Cohort Consortium (IHCC). This group gathered for the First International Cohort Summit in the USA in 2018 followed by a Second Summit in Iceland in 2019. During planning of the Third Summit to take place in Santiago, Chile, the global outbreak of COVID-19 required a transition to virtual meeting format. Approximately 160 attendees from more than 23 countries attended the virtual Summit. The event in Santiago, Chile will be postponed to a date to be determined when attendee health and safety will not be at heightened risk due to COVID-19. The virtual meeting objectives included: To galvanize the IHCC around a visionary charter and path forward (defining the IHCC organization, mission, membership, partnership opportunities, industry engagement). To examine how IHCC can rapidly mobilize worldwide cohorts to address the COVID-19 pandemic. To introduce the IHCC to a Cohort Data Atlas that can be used to stimulate and enable collaborations among cohorts.
    [Show full text]
  • COVID-19 Vaccine Development, Strategy and Implementation
    Symposium: Vaccines and Global Health: COVID-19 Vaccine Development, Strategy and Implementation The Program in Vaccine Education at the Columbia University Vagelos College of Physicians & Surgeons’ mission is to educate medical students and to inform health care professionals, public health experts, academic, government and industry researchers, policy makers, global health non-governmental organizations, journalists, and the general public as to the cutting-edge advances and challenges in modern vaccine development. The Columbia University convenors are Drs. Lawrence Stanberry (Co-Director, PVE), Philip LaRussa (Co-Director, PVE), Wilmot James (Associate Director, PVE), and Marc Grodman (Special Advisor, PVE). We have put together a group of 25 outstanding speakers who have been intimately involved with all aspects of COVID-19 vaccine development, strategy, and implementation. We are delighted to present this five-day virtual symposium at the cusp of the world’s transition to controlling the COVID-19 pandemic. Monday, February 22 National, Regional and Global Response to an Unprecedented Challenge 12:00-12:10 Welcome: Lee Bollinger, JD – President, Columbia University 12:10-12:15 Moderator: Lawrence R. Stanberry, MD, PhD – Director of the Programs in Global Health, Columbia University Vagelos College of Physicians and Surgeons 12:15-12:45 Keynote: Sir Jeremy Farrar, BSc, MBBS, PhD – Director, Wellcome Trust The Role of the Wellcome Trust in COVID-19 Vaccine Preparedness 12:45-1:30 Speakers: - Shabir Madhi, MBChB, MMed, FCPaeds PhD – Professor of Vaccinology, University of the Witwatersrand – A South African perspective on vaccine preparedness and availability. - Nancy Messonnier, MD – Director, National Center for Immunization and Respiratory Diseases, US CDC – A US CDC perspective on vaccine preparedness and availability.
    [Show full text]